Spots Global Cancer Trial Database for stage iv melanoma
Every month we try and update this database with for stage iv melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer | NCT00004135 | Kidney Cancer Melanoma (Skin) | filgrastim therapeutic all... cyclophosphamid... fludarabine pho... peripheral bloo... | 18 Years - 65 Years | University of Chicago | |
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | NCT01133977 | Stage IV Melano... | Lenvatinib Lenvatinib Dacarbazine | 18 Years - | Eisai Inc. | |
| Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma | NCT00053781 | Melanoma (Skin) | perifosine | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain | NCT00039572 | Brain and Centr... Melanoma (Skin) Metastatic Canc... | boronophenylala... | 18 Years - | National Cancer Institute (NCI) | |
| Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy | NCT00897520 | Melanoma (Skin) | recombinant int... proteomic profi... immunoenzyme te... laboratory biom... | - 120 Years | Eastern Cooperative Oncology Group | |
| Irofulven in Treating Patients With Stage IV Melanoma | NCT00005968 | Melanoma (Skin) | irofulven | 18 Years - | University of Colorado, Denver | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00056134 | Melanoma (Skin) | Dendritic cell ... | 18 Years - 120 Years | University Hospital Erlangen | |
| BMS-247550 in Treating Patients With Stage IV Melanoma | NCT00036764 | Recurrent Melan... Stage IV Melano... | ixabepilone pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00007969 | Melanoma (Skin) | Detox-B adjuvan... verteporfin | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | NCT00514085 | Melanoma (Skin) | recombinant hum... immunohistochem... laboratory biom... pharmacological... | 18 Years - | Canadian Cancer Trials Group | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | NCT04670445 | Stage IV Melano... Advanced Lung C... Stage IV Non-Sm... Unresectable No... Unresectable St... Small Cell Lung... Stage IV Merkel... Stage IV Cutane... Stage IV Basal ... Stage IV Breast... Stage IV Colore... Stage IV Gastri... Stage IV Esopha... Stage IV Hepato... Stage IV Renal ... Stage IV Bladde... Stage IV Head a... Stage IV Cervic... Stage IV Endome... Stage IV Mesoth... Immunotherapy Immune Checkpoi... | Educational Vid... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | NCT01519427 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | Akt inhibitor M... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045149 | Melanoma (Skin) | aldesleukin therapeutic tum... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma | NCT00081042 | Melanoma (Skin) | paclitaxel albu... | 18 Years - | National Cancer Institute (NCI) | |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00667901 | Melanoma (Skin) | riluzole protein express... reverse transcr... western blottin... immunohistochem... laboratory biom... pharmacological... neoadjuvant the... therapeutic con... | 18 Years - | Rutgers, The State University of New Jersey | |
| Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00002669 | Melanoma (Skin) | aldesleukin recombinant int... cisplatin dacarbazine | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | NCT02013492 | Male Breast Can... Recurrent Melan... Stage IV Breast... Stage IV Melano... Stage IV Ovaria... Stage IV Ovaria... Unspecified Adu... Hepatocellular ... | propranolol hyd... Correlative Stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma | NCT00005057 | Melanoma (Skin) | adenovirus RSV-... ganciclovir | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer | NCT00020540 | Kidney Cancer Melanoma (Skin) | recombinant CD4... recombinant flt... | 16 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Metastatic Malignant Melanoma | NCT00024011 | Recurrent Melan... Stage IV Melano... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | NCT00077532 | Melanoma (Skin) | gp100 antigen incomplete Freu... ipilimumab | 16 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery | NCT00450372 | Melanoma (Skin) | ADI-PEG-20 Pharmacology St... | 18 Years - 120 Years | University of Miami | |
| Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00112476 | Recurrent Melan... Recurrent Renal... Stage IV Melano... Stage IV Renal ... Unspecified Adu... | bryostatin 1 temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma | NCT00074230 | Melanoma (Skin) | Autologous Dend... | 18 Years - | University Hospital Erlangen | |
| Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT00289640 | Melanoma | ipilimumab (MDX... Ipilimumab Ipilimumab | 16 Years - | Bristol-Myers Squibb | |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00667901 | Melanoma (Skin) | riluzole protein express... reverse transcr... western blottin... immunohistochem... laboratory biom... pharmacological... neoadjuvant the... therapeutic con... | 18 Years - | Rutgers, The State University of New Jersey | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00004025 | Melanoma (Skin) | aldesleukin dendritic cell-... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | NCT00492440 | Kidney Cancer Melanoma (Skin) | recombinant int... gene expression... polymerase chai... protein express... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... pharmacological... | 18 Years - | Cytheris SA | |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma | NCT00004244 | Kidney Cancer Melanoma (Skin) | recombinant int... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| BMS-247550 in Treating Patients With Stage IV Melanoma | NCT00036764 | Recurrent Melan... Stage IV Melano... | ixabepilone pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | NCT00471887 | Melanoma (Skin) | CP-675,206 | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma | NCT00276536 | Breast Cancer Kidney Cancer Lymphoma Melanoma Multiple Myelom... Sarcoma Unspecified Adu... | recombinant int... IFN | 18 Years - 120 Years | The Cleveland Clinic | |
| Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | NCT00324623 | Melanoma (Skin) | Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Centre Hospitalier Universitaire Vaudois | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | NCT00453050 | Melanoma (Skin) Metastatic Canc... | imiquimod indocyanine gre... flow cytometry immunologic tec... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | NCT03235245 | Unresectable St... Stage IV Melano... | Nivolumab + Ipi... Encorafenib + B... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00085397 | Melanoma (Skin) | autologous dend... gp100 antigen therapeutic aut... | - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00004184 | Melanoma (Skin) | monoclonal anti... sargramostim alum adjuvant | 18 Years - | University of Alabama at Birmingham | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma | NCT00003091 | Kidney Cancer Melanoma (Skin) | aldesleukin recombinant int... | 18 Years - | Hoag Memorial Hospital Presbyterian | |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma | NCT01127451 | Stage IIIC Mela... Stage IV Melano... | Denileukin dift... | 18 Years - | Eisai Inc. | |
| Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | NCT00357461 | Melanoma (Skin) | gp100:209-217(2... gp100:280-288(2... incomplete Freu... ipilimumab | 16 Years - | Bristol-Myers Squibb | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | NCT00550654 | Kidney Cancer Melanoma (Skin) Metastatic Canc... Ovarian Cancer Sarcoma Unspecified Adu... | questionnaire a... 3-dimensional c... hypofractionate... image-guided ra... tomotherapy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| Radiation Use During Vemurafenib Treatment | NCT01843738 | BRAFV600 Mutati... Stage IV Melano... | Radiation thera... Vemurafenib | 18 Years - | University of Utah | |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | NCT06416085 | Advanced Cancer Stage IV Solid ... Stage IV Sarcom... Stage IV Lympho... Stage IV Melano... Endocrine Cance... | Psilocybin | 18 Years - | University Health Network, Toronto | |
| Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | NCT00602576 | Melanoma (Skin) | sorafenib tosyl... temozolomide | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00003346 | Melanoma (Skin) | acetaminophen acetylcysteine carmustine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma | NCT00006233 | Melanoma (Skin) | therapeutic all... cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | 18 Years - 64 Years | Fred Hutchinson Cancer Center | |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | NCT00436605 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | NCT00863330 | Melanoma (Skin) | Tumor Infiltrat... | 18 Years - | Aurora Health Care | |
| PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma | NCT00049530 | Melanoma (Skin) | PEG-interferon ... | 18 Years - | Eastern Cooperative Oncology Group | |
| Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | NCT00316901 | Kidney Cancer Melanoma (Skin) | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | NCT01339663 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... aldesleukin autologous tumo... laboratory biom... immunologic tec... immunohistochem... polymerase chai... therapeutic aut... | 18 Years - | Fred Hutchinson Cancer Center | |
| Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | NCT00404235 | Melanoma (Skin) | carboplatin paclitaxel albu... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | NCT00453050 | Melanoma (Skin) Metastatic Canc... | imiquimod indocyanine gre... flow cytometry immunologic tec... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | NCT00199342 | Stage IV Melano... | KW-2871 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | NCT00863330 | Melanoma (Skin) | Tumor Infiltrat... | 18 Years - | Aurora Health Care | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment | NCT00022438 | Melanoma (Skin) | aldesleukin incomplete Freu... recombinant tyr... | 16 Years - | National Cancer Institute (NCI) | |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | NCT00281957 | Recurrent Melan... Stage IV Melano... | sorafenib tosyl... tipifarnib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Metastatic Malignant Melanoma | NCT00060125 | Recurrent Melan... Stage IV Melano... | tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | NCT00082875 | Stage III Melan... Stage IV Melano... | cilengitide pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | NCT00003229 | Melanoma (Skin) | aldesleukin gp100 antigen tyrosinase pept... | 18 Years - 75 Years | Duke University | |
| An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | NCT01136967 | Unresectable St... Stage IV Melano... | Lenvatinib | 18 Years - 99 Years | Eisai Inc. | |
| E7070 in Treating Patients With Stage IV Melanoma | NCT00014625 | Melanoma (Skin) | indisulam | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Radiation Use During Vemurafenib Treatment | NCT01843738 | BRAFV600 Mutati... Stage IV Melano... | Radiation thera... Vemurafenib | 18 Years - | University of Utah | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | NCT00301067 | Metastatic Mela... | Calcitriol Temozolomide | 18 Years - | Northwestern University | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
